

## References

- Aarts, M., Liu, Y., Liu, L., et al. (2002). Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. *Science*, *298*, 846–850.
- Agre, P., King, L. S., Yasui, M., et al. (2002). Aquaporin water channels—from atomic structure to clinical medicine. *Journal of Physiology*, *542*, 3–16.
- Aktan, A. O., & Yalcin, A. S. (1998). Ischemia-reperfusion injury, reactive oxygen metabolites, and the surgeon. *Turkish Journal of Medical Sciences*, *28*, 1–5.
- Allen, C. L., & Bayraktutan, U. (2009). Oxidative stress and its role in the pathogenesis of ischaemic stroke. *International Journal of Stroke*, *4*, 461–470.
- Bano, D., Young, K. W., Guerin, C. J., et al. (2005). Cleavage of the plasma membrane  $\text{Na}^+/\text{Ca}^{2+}$  exchanger in excitotoxicity. *Cell*, *120*, 275–285.
- Bazan, N. G. (2005). Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. *Brain Pathology*, *15*, 159–166.
- Bazan, N. G. (2009). Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. *Journal of Lipid Research*, *50*, S400–S405.
- Belayev, L., Busto, R., Zhao, W., et al. (1996). Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. *Brain Research*, *739*, 88–96.
- Belayev, L., Khoutorova, L., Atkins, K. D., et al. (2009). Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. *Stroke*, *40*, 3121–3126.
- Belayev, L., Khoutorova, L., Atkins, K. D., et al. (2011, March). Docosahexaenoic acid therapy

- of experimental ischemic stroke. *Translational Stroke Research* (In press).
- Belayev, L., Liu, Y., Zhao, W., et al. (2001). Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. *Stroke*, *32*, 553–560.
- Belayev, L., Marcheselli, V. L., Khoutorova, L., et al. (2005). Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. *Stroke*, *36*, 118–123.
- Belayev, L., Pinard, E., Nallet, H., et al. (2002). Albumin therapy of transient focal cerebral ischemia: *In vivo* analysis of dynamic microvascular responses. *Stroke*, *33*, 1077–1084.
- Belayev, L., Saul, I., Huh, P. W., et al. (1999). Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. *Brain Research*, *845*, 107–111.
- Borsello, T., Clarke, P. G., Hirt, L., et al. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. *Nature Medicine*, *9*, 1180–1186.
- Clark, W. M. (2009). Efficacy of citicoline as an acute stroke treatment. *Expert Opinion on Pharmacotherapy*, *10*, 839–846.
- Connolly, E. S., Winfree, C. J., Springer, T. A., et al. (1996). Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. *Journal of Clinical Investigation*, *97*, 209–216.
- Dankbaar, J. W., Hom, J., Schneider, T., et al. (2010). Dynamic perfusion–CT assessment of early changes in blood–brain barrier permeability of acute ischaemic stroke patients. *Journal of Neuroradiology*.
- de Groot, H., & Rauen, U. (2007). Ischemia–reperfusion injury: Processes in pathogenetic networks: A review. *Transplantation Proceedings*, *39*, 481–484.
- del Zoppo, G. J. (2006). Stroke and neurovascular protection. *The New England Journal of*

- Medicine*, 354, 553–555.
- del Zoppo, G. J., Schmid-Schönbein, G. W., Mori, E., et al. (1991). Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. *Stroke*, 22, 1276–1283.
- Dobbin, J., Crockard, H. A., & Ross-Russell, R. (1989). Transient blood–brain barrier permeability following profound temporary global ischaemia: An experimental study using 14C-AIB. *Journal of Cerebral Blood Flow and Metabolism*, 9, 71–78.
- Ebinger, M., De Silva, D. A., Christensen, S., et al. (2009). Imaging the penumbra—strategies to detect tissue at risk after ischemic stroke. *Journal of Clinical Neuroscience*, 16, 178–187.
- Faulkner, J. R., Herrmann, J. E., Woo, M. J., et al. (2004). Reactive astrocytes protect tissue and preserve function after spinal cord injury. *The Journal of Neuroscience*, 24, 2143–2155.
- Fisher, M. (2006). The ischemic penumbra: A new opportunity for neuroprotection. *Cerebrovascular Diseases*, 2, 64–70.
- Fisher, M. (2011). New approaches to neuroprotective drug development. *Stroke*, 42, S24–S27.
- Fiskum, G., Murphy, A. N., & Beal, M. F. (1999). Mitochondria in neurodegeneration: Acute ischemia and chronic neurodegenerative diseases. *Journal of Cerebral Blood Flow and Metabolism*, 19, 351–369.
- Ginsberg, M. D., Palesch, Y. Y., Martin, R. H., et al. (2011). The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2. *Stroke*, 42, 119–127.
- Grotta, J. (2001). and combination therapy stroke trial investigators. combination therapy stroke trial: Recombinant tissue-type plasminogen activator with/without lubeluzole. *Cerebrovascular Diseases*, 12, 258–263.

- Haddad, G. G., & Jiang, C. (1997). O<sub>2</sub>-sensing mechanisms in excitable cells: Role of plasma membrane K<sup>+</sup> channels. *Annual Review of Physiology*, *59*, 23–42.
- Hall, A. A., & Pennypacker, K. R. (2010). Implications of immune system in stroke for novel therapeutic approaches. *Translational Stroke Research*, *1*, 85–95.
- Hall, E. D., Andrus, P. K., Smith, S. L., et al. (1996). Neuroprotective efficacy of microvascularly localized versus brain-penetrating antioxidants. *Acta Neurologica Supplementum*, *66*, 107–113.
- Halliwell, B. (1992). Reactive oxygen species and the central nervous system. *Journal of Neurochemistry*, *59*, 1609–1623.
- Hardingham, G. E., & Bading, H. (2010). Synaptic versus extra-synaptic NMDA receptor signaling: Implications for neurodegenerative disorders. *Nature Reviews Neuroscience*, *11*, 682–696.
- Heiss, W. D. (2010). The concept of the penumbra: Can it be translated to stroke management?. *International Journal of Stroke*, *5*, 290–295.
- Hossmann, K. M. A. (2009). Pathophysiological basis of translational stroke research. *Folia Neuropathologica*, *47*, 213–227.
- Jin, R., Yang, G., & Li, G. (2010). Molecular insights and therapeutic targets for blood–brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator. *Neurobiology of Disease*, *38*, 376–385.
- Kleindorfer, D., Kissela, B., Schneider, A., et al. (2004). Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. *Stroke*, *35*, 27–29.
- Kloska, S. P., Wintermark, M., Engelhorn, T., et al. (2010). Acute stroke magnetic resonance

- imaging: Current status and future perspective. *Neuroradiology*, *52*, 189–201.
- Kristian, T., & Siesjo, B. K. (1997). Changes in ionic fluxes during cerebral ischaemia. *International Review of Neurobiology*, *40*, 27–45.
- Krupp, J. J., Vissel, B., Thomas, C. G., et al. (1999). Interactions of calmodulin and  $\alpha$ -actinin with the NR1 subunit modulate  $\text{Ca}^{2+}$ -dependent inactivation of NMDA receptors. *Journal of Neuroscience*, *19*, 1165–1178.
- Lee, J. K., Kwak, H. J., Piao, M. S., et al. (2010). Quercetin reduces the elevated matrix metalloproteinases-9 level and improves functional outcome after cerebral focal ischemia in rats. *Acta Neurologica*.
- Lipton, S. A. (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. *Nature Reviews Discovery*, *5*, 160–170.
- Lloyd-Jones, D., Adams, R., Carnethon, M., et al. (2009). Heart disease and stroke statistics—2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*, *119*, e21–e181.
- Lo, E. H., Broderick, J. P., & Moskowitz, M. A. (2004). tPA and proteolysis in the neurovascular unit. *Stroke*, *35*, 354–356.
- Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003). Mechanisms, challenges and opportunities in stroke. *Nature Reviews Neuroscience*, *4*, 399–415.
- Lucas, S. M., Rothwell, N. J., & Gibson, R. M. (2006). The role of inflammation in CNS injury and disease. *British Journal of Pharmacology*, *147*(Suppl. 1), s232–s240.
- Lukiw, W. J., Cui, J. G., Marcheselli, V. L., et al. (2005). A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. *Journal of Clinical Investigation*, *115*, 2774–2783.

- Lyden, P., Jacoby, M., Schim, J., et al. (2001). The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): Final results. *Neurology*, *57*, 1199–1205.
- Ma, J., Qiu, J., & Hirt, L., et al. (2001). Synergistic protective effect of caspase inhibitors and bFGF against brain injury induced by transient focal ischaemia. *British Journal of Pharmacology*, *133*, 345–350.
- Marcheselli, V. L., Hong, S., Lukiw, W. J., et al. (2003). Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. *The Journal of Biological Chemistry*, *278*, 43807–43817.
- Markus, R., Reutens, D. C., Kazui, S., et al. (2004). Hypoxic tissue in ischaemic stroke: Persistence and clinical consequences of spontaneous survival. *Brain*, *127*, 1427–1436.
- Mehta, S. L., Manhas, N., & Raghbir, R. (2007). Molecular targets in cerebral ischemia for developing novel therapeutics. *Brain Research Reviews*, *54*, 34–66.
- Minnerup, J., Heidrich, J., Wellmann, J., et al. (2008). Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. *Stroke*, *39*, 1855–1861.
- Molina, C. A. (2011). Reperfusion therapies for acute ischemic stroke: Current pharmacological and mechanical approaches. *Stroke*, *42*, S16–S19.
- Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010). The science of stroke: Mechanisms in search of treatments. *Neuron*, *67*, 181–198.
- Nakka, V. P., Gusain, A., Mehta, S. L., et al. (2008). Molecular mechanisms of apoptosis in cerebral ischemia: Multiple neuroprotective opportunities. *Molecular Neurobiology*, *37*, 7–38.

- Nicholls, D., & Attwell, D. (1990). The release and uptake of excitatory amino acids. *Trends in Pharmacological Sciences*, *11*, 462–468.
- Oku, N., Kashiwagi, T., Hatazawa, J., et al. (2010). Nuclear neuroimaging in acute and subacute ischemic stroke. *Annals of Nuclear Medicine*, *24*, 629–638.
- Palesch, Y. Y., Hill, M. D., Ryckborst, K. J., et al. (2006). The ALIAS Pilot Trial: A dose-escalation and safety study of albumin therapy for acute ischemic stroke—II: Neurologic outcome and efficacy analysis *Stroke* (37)
- Pan, J., Konostas, A. A., Bateman, B., et al. (2007). Reperfusion injury following cerebral ischemia: Pathophysiology, MR imaging, and potential therapies. *Neuroradiology*, *49*, 93–102.
- Pulsinelli, W. (1992). Pathophysiology of acute ischaemic stroke. *Lancet*, *339*, 533–536.
- Ramos-Cabrer, P., Campos, F., Sobrino, T., et al. (2011). Targeting the Ischemic Penumbra. *Stroke*, *42*, 7–11.
- Ramos-Fernandez, M., Bellolio, M. F., & Stead, L. G. (2011). Matrix metalloproteinase-9 as a marker for acute ischemic stroke: A systematic review. *Journal of Stroke and Cerebrovascular Diseases*, *20*, 47–54.
- Ringelstein, E. B., & Nabavi, D. G. (2005). Cerebral small vessel diseases: Cerebral microangiopathies. *Current Opinion in Neurology*, *18*, 179–188.
- Rivers, C. S., Wardlaw, J. M., Armitage, P. A., et al. (2006). Do acute diffusion- and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke?. *Stroke*, *37*, 98–104.
- Rodriguez de Turco, E. B., Belayev, L., Liu, Y., et al. (2002). Systemic fatty acid responses to transient focal cerebral ischemia: Influence of neuroprotectant therapy with human

- albumin. *Journal of Neurochemistry*, 83, 515–524.
- Rogalewski, A., Schneider, A., Ringelstein, E. B., et al. (2006). Toward a multimodal neuroprotective treatment of stroke. *Stroke*, 37, 1129–1136.
- Rothwell, N. J., & Luheshi, G. N. (2000). Interleukin 1 in the brain: Biology, pathology and therapeutic target. *Trends in Neurosciences*, 23, 618–625.
- Sage, J. I., Van Uitert, R. L., & Duffy, T. E. (1984). Early changes in blood brain barrier permeability to small molecules after transient cerebral ischemia. *Stroke*, 15, 46–50.
- Sandoval, K. E., & Witt, K. A. (2008). Blood–brain barrier tight junction permeability and ischemic stroke. *Neurobiology of Disease*, 32, 200–219.
- Schäbitz, W. R., Li, F., Irie, K., et al. (1999). Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. *Stroke*, 30, 42731.
- Schmid-Elsaesser, R., Hungerhuber, E., Zausinger, S., et al. (1999). Neuroprotective efficacy of combination therapy with two different antioxidants in rats subjected to transient focal ischemia. *Brain Research*, 816, 471–479.
- Schreiber, J., Eling, T. E., & Mason, R. P. (1986). The oxidation of arachidonic acid by the cyclooxygenase activity of purified prostaglandin H synthase: Spin trapping of a carbon-centered free radical intermediate. *Archives of Biochemistry and Biophysics*, 249, 126–136.
- Serhan, C. N., Yacoubian, S., & Yang, R. (2008). Anti-inflammatory and proresolving lipid mediators. *Annual Review of Pathology*, 3, 279–312.
- Sheng, H., Bart, R. D., Oury, T. D., et al. (1999). Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. *Neuroscience*, 88, 185–



- Simard, J. M., Sahuquillo, J., Sheth, K. N., et al. (2010). Managing malignant cerebral infarction. *Current Treatment Options in Neurology*.
- Simon, R. P., Swan, J. H., & Meldrum, B. S. (1984). Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. *Science*, *226*, 850–852.
- Simopoulos, A. P. (2008). The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Experimental Biology and Medicine (Maywood)*, *233*, 674–688.
- Singhal, A., Lo, E., Dalkara, T., et al. (2006). Ischemic Stroke: Basic Pathophysiology and Neuroprotective Strategies.: *Acute ischemic stroke. Part 1*. New York: Springer-Verlag Berlin Heidelberg.
- Smith, W. S. (2006). Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCi) trial, part I. *AJNR American Journal of Neuroradiology*, *27*, 1177–1182.
- Sugawara, T., & Chan, P. H. (2003). Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. *Antioxidants & Redox Signaling*, *5*, 597–607.
- Thomas, C. G., Miller, A. J., & Westbrook, G. L. (2006). Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. *Journal of Neurophysiology*, *95*, 1727–1734.
- Trotti, D., Rizzini, B. L., Rossi, D., et al. (1997). Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. *The European Journal of Neuroscience*, *9*, 1236–1243.

- Tu, W., Xu, X., Peng, L., et al. (2010). DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke. *Cell*, *140*, 222–234.
- Van Eldik, L. J. (2002). Structure and enzymology of a death--associated protein kinase. *Trends in Pharmacological Sciences*, *23*, 302–304.
- Wang, J., Liu, S. H., Fu, Y. P., et al. (2003). Cdk5 activation induces CA1 pyramidal cell death by direct phosphorylation of NMDA receptors. *Nature Neuroscience*, *6*, 1039–1047.
- Ward, R. E., Huang, W., Curran, O. E., et al. (2010). Docosahexaenoic acid prevents white matter damage after spinal cord injury. *Journal of Neurotrauma*, *27*, 1769–1780.
- Weiss, N., Miller, F., Cazaubon, S., et al. (2009). The blood–brain barrier in brain homeostasis and neurological diseases. *Biochimica et Biophysica Acta*, *1788*, 842–857.
- Welch, K. M. A., Caplan, L. R., Reis, D. J., Siesjo, B. K., & Weir, B. (Eds.), (1997). *Primer on cerebrovascular diseases*. San Diego, CA: Academic Press.
- White, B. C., Sullivan, J. M., DeGracia, D. J., et al. (2000). Brain ischemia and reperfusion: Molecular mechanisms of neuronal injury. *Journal of Neurological Sciences*, *179*, 1–33.
- Xiong, Z. G., Zhu, X. M., Chu, X. P., Minami, M., Hey, J., Wei, W. L., et al. (2004). Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels. *Cell*, *118*, 687–698.
- Yamashita, T., Deguchi, K., Nagotani, S., et al. (2010). Vascular protection and restorative therapy in ischemic stroke. *Cell Transplant*
- Zador, Z., Stiver, S., Wang, V., et al. (2009). Role of aquaporin-4 in cerebral edema and stroke. *Handbook of Experimental Pharmacology*, *190*, 159–170.
- Zhang, L., Zhang, Z. G., Liu, X., et al. (2006). Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. *Thrombosis and*

*Haemostasis*, 95, 166–173.

Zhang, R. L., Chopp, M., Chen, H., et al. (1994). Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat. *Journal of Neurological Sciences*, 125, 3–10.

Zou, Y., Chen, C. H., Fike, J. R., et al. (2009). A new mouse model for temporal- and tissue-specific control of extracellular superoxide dismutase. *Genesis*, 47, 142–154.